Pharmacokinetic interaction study between ivabradine with fluoxetine or metronidazole in healthy volunteers

Farmacia

Volumn 58, Issue 4, 2010, Pages 471-477

  Vlase, Laurian ^a   Popa, Adina ^a   Neag, Maria ^a   Muntean, Dana ^a   Leucuţa, Sorin E ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Fluoxetine; Ivabradine; Metronidazole; Pharmacokinetic interaction

Indexed keywords

CORLENTOR; FLUOXETINE; FLUOXIN; IVABRADINE; METRONIDAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; SINGLE DRUG DOSE; STATISTICAL ANALYSIS;

EID: 77955448342     PISSN: 00148237     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Prasad U.K, Gray D., Purcell H., Review of the I-f selective channel inhibitor ivabradine in the treatment of chronic stable angina, Advances In Therapy, 2009, 26(2):127-137.
2. Khawaja M.Z., Walker D.M., Ivabradine - the beauty of a slow heart rate, International Journal Of Clinical Practice, 2009, 63(4): 542-546.
3. Tardif J.C., Ponikowski P., Kahan T., Efficacy of the I-f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial, European Heart Journal, 2009, 30(5):540-548.
4. Milliez P., Messaoudi S., Nehme J., Rodriguez C., Samuel J.L., Delcayre C., : Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure, American Journal Of Physiology-Heart And Circulatory Physiology, 2009, 296(2): H435-H441.
5. Riccioni G., Vitulano N., D'Orazio N., Ivabradine: Beyond heart rate control, Advances In Therapy, 2009, 26(1):12-24.
6. Portoles A., Calvo A., Terleira A., Laredo L., Resplandy G., Gorostiaga C., Moreno A., Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: An open-label, randomized, crossover, pharmacokinetic interaction clinical trial, Journal of Clinical Pharmacology, 2006, 46(10):1195-1203.
7. Portoles A., Terleira A., Calvo A., Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: An open-label, pharmacokinetic interaction clinical trial, Journal Of Clinical Pharmacology, 2006, 46(10): 1188-1194
8. Altamura A.C., Moro A.R., Percudani M., Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994; 26(3):201-214.
9. Baumann P., Rochat B., Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol. 1995; 10(1):15-21.
10. Roedler R., Neuhauser M.M., Penzak S.R., Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?, Ann Pharmacother. 2007;41(4):653-658.
11. Vlase L., Muntean D., Leucuta S. E., Baldea I., High-throughput determination of ivabradine from human plasma by LC/MS/MS and its application to pharmacokinetic studies, Studia Universitatis Babes-Bolyai Chemia, 2009; 54(2):43-52.
12. http://www.thermo.com/eThermo/CMA/PDFs/Product/productPDF-27347.pdf
13. U. S. Department of Health and Human Services, Food and Drug Administration, Bioavailability and Bioequivalence Studies for Orally Administrated Drug Products - General Considerations, Rockville, USA, 2003, http://www.fda.gov/cder/guidance/index.htm
14. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, London, UK, 2001 (CPMP/EWP/QWP/1401/98).
15. Sandulovici R., Prasacu I., Mircioiu C., Voicu V., Medvedovici A., Anuţa V., Mathematical and phenomenological criteria in selection of pharmacokinetic model for m1 metabolite of pentoxyphylline, Farmacia, 2009, 57(2):235-246.
16. Pop A., Vlase L., Leucuţa S.E., Pharmacokinetic study of felodipine after single oral dose of slow release formulations in healthy volunteers, Farmacia, 2008, 56(5):474-482.
17. Rãdulescu F., Miron D., Mircioiu C., Voicu V., Distribution profiles of drugs with active metabolites by compartmental analysis, Farmacia, 2007, 55(4):390-395.
18. Anuţa V., Aldea A., Neagu O., Mircioiu I., Miron D., Radulescu F., Soare-Rada M., Enache V., Bioequivalence estimation based on peak areas of unknown metabolites, Farmacia, 2007, 55(6):680-690.